The company continues to move toward its planned merger with German diagnostics firm Curetis, which is expected to close early next year.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
Opko logged $181.1 million in revenues from services, $26.2 million in revenue from products, and $21.5 million from licensing and intellectual property.
The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
For fiscal 2020, BD provided guidance for revenue growth in the 4 to 4.5 percent range, or 5 to 5.5 percent on a currency-neutral basis.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
NanoString logged $30.6 million in revenues in the third quarter, beating the Wall Street estimate of $28.1 million.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The company is preparing to submit new versions of its immunohematology and serological disease screening microarrays to US and European regulators next year.